Explore

Trendline Trendline
Spruce Biosciences Reports Financial Results and Advances TA-ERT Program for MPS IIIB

Spruce Biosciences Reports Financial Results and Advances TA-ERT Program for MPS IIIB

Spruce Biosciences Reports Financial Results and Advances TA-ERT Program for MPS IIIB
Trendline Trendline
Spruce Biosciences Reports Q1 2026 Financial Results and Strategic Developments

Spruce Biosciences Reports Q1 2026 Financial Results and Strategic Developments

Spruce Biosciences Reports Q1 2026 Financial Results and Strategic Developments
Trendline Trendline
Spruce Biosciences Strengthens Financial Position Ahead of Potential U.S. Launch of TA-ERT

Spruce Biosciences Strengthens Financial Position Ahead of Potential U.S. Launch of TA-ERT

Spruce Biosciences Strengthens Financial Position Ahead of Potential U.S. Launch of TA-ERT
Trendline Trendline
Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI

Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI

Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI
Trendline Trendline
Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy

Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy

Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy
Trendline Trendline
INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107

INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107

INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107
Trendline Trendline
Atara Biotherapeutics Reports Significant Revenue Decline and Operational Updates for Q1 2026

Atara Biotherapeutics Reports Significant Revenue Decline and Operational Updates for Q1 2026

Atara Biotherapeutics Reports Significant Revenue Decline and Operational Updates for Q1 2026
Trendline Trendline
INOVIO Announces First Quarter 2026 Financial Results and Advances in DNA Medicine Development

INOVIO Announces First Quarter 2026 Financial Results and Advances in DNA Medicine Development

INOVIO Announces First Quarter 2026 Financial Results and Advances in DNA Medicine Development
Trendline Trendline
Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results
Trendline Trendline
Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress

Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress

Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress
Trendline Trendline
Palatin Technologies Reports Q3 2026 Financial Results and Business Progress

Palatin Technologies Reports Q3 2026 Financial Results and Business Progress

Palatin Technologies Reports Q3 2026 Financial Results and Business Progress
Trendline Trendline
Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call

Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call

Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call